Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (3805)	5/2/1998 2:46:00 PM
From: LoLoLoLita	Respond to of 7041

ClaudB, Correct. FDA should have no problem with articles published in peer-reviewed journals. But they do get very upset if preliminary results are publicized in the press prior to the scientific publication. A poster put up at a conference is somewhere between the mass media and a peer-reviewed article. They are generally only reviewed for relevance of the topic to the conference, and the credentials of the investigators are looked at--for example, the American Nuclear Society meetings, to best of my knowledge, do not have presentations by Greenpeace. It can vary with the type of meeting and the sponsoring organization, but posters are generally not considered as peer-reviewed. If the AUA ZONA/Vasomax poster just shows the efficacy results from the crossover study that Linda posted here (without giving all the details of the experimental protocols such as pre-screening, demography of the population, etc.) then it could be considered to be questionable. Due to the politics of ED, my guess is that all the competing companies will be scrutinizing each others presentations, and if they feel anything is not kosher, they'll complain to the FDA. David

To: Claud B who wrote (3805)	5/2/1998 2:50:00 PM
From: robert elmasian	Read Replies (2) \| Respond to of 7041

TO ALL, does anyone know what ZONA has done or plans to do with the SGP money. What are the requirements for getting more funding? Also, does anyone agree or disagree with the following ZONA data or have things changed? Employees 40 Shares Outstanding (mil) 11.25 EPS ($) (1.92) Float (mil) 6.73 Cash Flow Per Share 1.84 Bob